Telaprevir combination therapy induced a sustained virologic response in nonresponsive chronic HCV infection

Reichen, Juerg
August 2010
ACP Journal Club;8/17/2010, Vol. 153 Issue 2, p6
Academic Journal
The article reports on a study focusing on the effectiveness of telaprevir combination therapy in inducing sustained virologic response (SVRs) in nonresponsive chronic hepatitis C virus (HCV) infection. The results of the study showed that patients in telaprevir groups were more likely to have SVRs than patients in the control group. However, the pharmacokinetics and side-effect profile of telaprevir are still need to be addressed.


Related Articles

  • The Role of P-Glycoprotein in the Pharmacokinetics and Tissue Distribution of a Hepatitis C Virus Protease Inhibitor. Chen, Kevin X.; Vibulbhan, Bancha; Tongtong Liu; Broske, Lisa; Genfeng Wang; Cheng Li; Njoroge, F. George; Uss, Annette S.; Cheng, K.-C. // Drug Metabolism Letters;Dec2009, Vol. 3 Issue 4, p290 

    S5, a hepatitis C virus protease inhibitor, displays partially saturable efflux in the Caco-2 system. In addition, the efflux can be reversed by cyclosporine, indicating that S5 may be a human Pglycoprotein (P-gp) substrate. S5 can also activate the ATPase activity in vesicle membranes...

  • Virology: The keys to hepatitis entry.  // Nature;4/28/2011, Vol. 472 Issue 7344, p392 

    The article discusses a research on a new possible way to prevent hepatitis C virus (HCV) entry in humans through blocking two cell-surfaced proteins, namely EGFR and EphA2.

  • Hepatitis C and Poor Quality of Life: Is it the Virus or the Patient? Abdo, Ayman A. // Saudi Journal of Gastroenterology;Jul2008, Vol. 14 Issue 3, p109 

    Hepatitis C is a systemic disease that has many extrahepatic manifestations in addition to hepatic inflammation and fibrosis, some of which may result in a poor health-related quality of life (HRQOL). Fatigue is perhaps the most frequent and disabling extrahepatic symptom of hepatitis C virus...

  • The new era of hepatitis C treatment: still the tip of the iceberg? GASBARRINI, A.; PONZIANI, F. R.; ANNICHIARICO, B. E.; SICILIANO, M.; CRAXÌ, A. // European Review for Medical & Pharmacological Sciences;Sep2013, Vol. 17 Issue 17, p2271 

    The author discusses the new age of hepatitis C treatment. The revolution of hepatitis C virus (HCV) infection treatment began in the early 1990s, with the introduction of interferon (IFN) alpha, but the optimal results have been attained in the recent years. Hepatitis C, far from the...

  • In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. Pietschmann, Thomas // Gut;Sep2014, Vol. 63 Issue 9, p1375 

    The article presents the author's views on Hepatitis C virus infection of primary human hepatocytes. HCV developed suitable cell culture and animal models to dissect mechanism of virus replication and liver disease. It further discusses a study that investigate infection of primary liver cells...

  • Prognostic role of serum interleukin-18 in Egyptian patients with hepatitis c virus-related hepatocellular carcinoma treated by radiofrequency ablation. Mohran, Z.; Abdelkader, N. A.; Abdelmoez, A. T.; Abolmaaty, M. E.; Abbas, A. A.; Abdelfattah, M. // Indian Journal of Cancer;Jul-Sep2014, Vol. 51 Issue 3, p342 

    AIM: The aim of this study is to identify the prognostic value of serum interleukin (IL)-18 level in hepatitis C virus (HCV) -related hepatocellular carcinoma (HCC) patients. MATERIALS AND METHODS: This study was conducted in Tropical Medicine department and HCC unit in Ain Shams University...

  • Peginterferon-α.  // Reactions Weekly;10/13/2007, Issue 1173, p22 

    The article describes the case of an approximately 54-year-old woman who has experienced an exacerbation of her pre-existing Graves' ophthalmopathy during treatment with peginterferon-&aalpha; for chronic hepatitis C virus infection. After her upper eyelid recession, in 2005, she presented with...

  • Thermal stability and inactivation of hepatitis C virus grown in cell culture. Hongshuo Song; Jin Li; Shuang Shi; Ling Yan; Hui Zhuang; Kui Li // Virology Journal;2010, Vol. 7, p40 

    Background: Hepatitis C virus (HCV) is a blood-borne flavivirus that infects many millions of people worldwide. Relatively little is known, however, concerning the stability of HCV and reliable procedures for inactivating this virus. Methods: In the current study, the thermostability of cell...

  • Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile.  // PharmacoEconomics & Outcomes News;11/19/2005, Issue 491, p9 

    The article discusses research being done on the cost effectiveness of evaluating early virological response of peginterferon-alpha-2b plus ribavirin therapy in patients with chronic hepatitis C virus genotype 1. It references a study by M. Buti et al published in a 2005 issue of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics